The resurgence of infectious diseases on the African continent plays a major role in the increase in cancer occurrence. Whereas in developed countries the causes of occurrence of cancers are related mainly to non-infectious factors; cancers of infectious origin become a dramatic particularity in Africa. The proportion of virus-induced cancers may reach up to 75% of cancer cases in certain countries. Oncogenic viruses such as human papilloma virus (HPV), hepatitis viruses B and C, human herpes virus 8 and Epstein Barr virus in association with human immunodeficiency virus are the main viral etiologies of cancers in Africa, representing around 30% of cancers causes. Optimistically, 30% of cancers could be prevented in Africa. However, health burden prevails on the continent due to the weakness of health policy especially regarding preventive medicine, but also the limited technical facilities, poor manpower and insufficient political commitment. We felt urgent to review the state of the art of the question, and necessary to analyze and publicize the current epidemiological advances in oncogenic viruses and virus-induced cancers in Africa. Prevention implies understanding, which is compulsory to reverse the current trends and to potentially instate a control of virus-induced cancers.
countries and the second in developing countries [1] . In 2008, the World Health Organization (WHO) gave the estimate of 12.7 million new cases of cancer worldwide with 7.6 million deaths (nearly 13% of global mortality). Approximately 70% of cases occurred in southern countries [2] [3] . Estimates for 2030 and 2050 indicate that mortality may respectively exceed 13.1 and 17.5 million deaths for 22 and 27 million new cases worldwide of which 95% will occur in southern countries [1] [4] . These very clear differences in incidence and mortality reflect differences in exposure to determinant risk factors such as infectious diseases, e.g., in Africa. In 2008 also, other statistics showed that 2 million new cancer cases (16.1%) worldwide are caused by infectious diseases of which approximately 33% occurred in sub-Saharan Africa. Bacteria (Helicobacter pylori-associated gastric cancer), parasites (Schistosoma haematobium-associated bladder cancer) and viruses were the main causative etiology [5] .
Epidemiological and molecular studies have identified eight viruses that induce or promote cancer occurrence in humans: hepatitis B (HBV) and C (HCV) viruses, Epstein-Barr virus (EBV), human papillomavirus (HPV), human T lymphotropic virus type 1(HTLV-1), human herpes virus 8 (HHV8), Kaposi's sarcoma herpes virus-8 (KSHV-8), and also human immunodeficiency virus (HIV1 and 2).
These viruses are often found in coinfection [6] [7] .
Viral involvement in cancer occurrence in Africa may represent an opportunity, as it reflects a hope to significantly reduce cancer incidence and mortality through prevention and/or treatment of viral infections. Our purpose was therefore to review recent advances in epidemiological and control aspects of virus-induced cancers, as well as the molecular biology of viral carcinogenesis in the particular context of the African continent.
Methodology
A thorough literature search was undertaken to dig-up and review recent articles from the PubMed database (National Library of Medicine-National Institutes of Health) using the following key words: "transforming virus", "persistent infection", "cancer in Africa", "viruses and cancer", "cancer epidemiology", "molecular basis of cancer". Using access codes, articles in both French and English in relation to our thematic were selected from Science Direct and Springer Link.
Data presented at international conferences and published in abstract form were also of interest. Finally, articles published in "Médecine tropicale" and "Méde-cine d'Afrique Noire" were also analyzed and integrated in our database. Useful information from all items was summarized.
Burden of Cancer in Africa: Epidemiological Background
Sub-Saharan Africa is heavily affected by the continuous expansion of cancer with an annual incidence varying from 100 to 120 per 100,000 people. Mortality rates from cancer reach 75% depending on cancer type and country of concern [7] [8] .
In 2008, the number of deaths due to cancer in Africa stood at 512,402 (63%) 
Problem of Virus-Induced Human Cancers in Africa
It is now recognized that many cancers have an infectious etiology [4] . Between Virus-induced cancers represent a true African continents specificity, compared to cancers affecting developed countries that depend mainly on hormonal and genetic factors [14] . This particular etiological profile may be explained by several reasons other than weakness of health systems and lack of political will of Governors. Several armed conflicts ravage Africa, with immediate consequences such as The economic consequences of cancers of infectious origin, especially virus-induced cancers, impose to take appropriate measures to control viral diseases across the continent. It is our belief that improving public awareness of virus-induced cancer pathology may also represent a major axis of prevention [15] . In terms of human development, the WHO study through the International Agency for Research on Cancer (IARC) stated: "the evolution of the cancer burden in the world is based on human development as it is (?) mainly affecting some countries social and economic transition, ..." [3] .
Viral Mechanism of Carcinogenesis
Oncogenic DNA or RNA viruses are able to induce the formation of tumors. Transforming viral infections are still persistent, chronic, latent or abortive. The persistent viral genome integrates all or part of the DNA of the infected cell to persist as proviral form or remain in episomal form in the cytoplasm [16] .
Although the mechanism of viral oncogenesis depends on the type of virus, certain physiological or metabolic pathways are common to all cancers. The process of initiation and development of virus-induced cancers is due to an accumulation of anomalies leading to immortalization and physiological and morphological alterations that define the state of transformation, i.e., the increased viability in a poorer growth factor environment, the locking mechanisms of apoptosis and senescence, the exhaustion of the immune system, etc. [17] . These modifications involve either the activation of genes that stimulate cell proliferation (viral or cellular oncogenes) or inactivation of genes that inhibit cell growth (tumor suppressor genes), but also those involved in DNA repair [17] [18].
In general, oncogenesis induced by RNA viruses is based on insertion of a viral activator near a cellular proto-oncogene (insertional mutagenesis), or integration into the cellular genome of a viral oncogene activated while oncogenesis induced DNA viruses. Such an integration is based either on the inactivation of a cellular anti-oncogene (tumor suppressor gene) as p53 or pRb, or on mutations, or even on the insertion of the virus genome at a critical point in the cellular genome.
In some cases, the virus plays a prolonged role in the initiation of tumor in the persistence of the malignant phenotype [18] .
Tumor Viruses and Human Cancers Associated
Among the families of known human tumor viruses, the following can be distinguished: Retroviridae and Flaviviridae for RNA viruses; Hepadnaviridae, Herpesviridae and Papillomaviridae for DNA tumor viruses (Table 1) . 
Human Papillomavirus (HPV) and Cervical Cancer of the Uterus
HPVs are small viruses from 52 to 55 nm in diameter, non-enveloped, doublestranded DNA, circular, approximately 8000 bp with an icosahedral capsid. The family has more than 200 known genotypes for nearly 120 characterized HPV [19] . Fifteen HPV oncogenes classified as high risk (HR-HPV) are responsible for most malignancies associated with cervical cancer of the uterus [20] .
In terms of incidence and mortality, cervix cancers are respectively considered in 3rd and 4th class positions of all female cancers. Cervical cancers represent a global 9% (529,800) of all new cases and 8% (275,100) of all cancer deaths among women [21] . This low incidence results from the impact of efforts by Western countries for prevention, screening and treatment. However, the opposite curve is observed in southern countries where more than 85% of cases continue to be recorded. In Africa, cervical cancer remains the leading cause of death with 53.300 (19%) deaths for an incidence of 80.400 (21%) new cases, representing the second most common cancer among women in the continent. [22] .
The occurrence of cervical cancer is the result of a persistent infection of HR-HPV which is the most common STI caused by a virus. Their transforming power is linked to the activity of viral proteins E6, E7 and E5 [23] . 
Hepatitis Viruses B and C (HBV and HCV) and Hepatocellular Carcinoma
Viral hepatitis B virus presents the smallest human DNA genome with a 3,200
base pair double-stranded circular of 50% to 80% of its length. It encodes four genes: the C genes with a pre-core region (capsid or core) consisting of HBc antigen; the S genes, a zone with pre-S1 and pre-S2 (the envelope) consisting of HBsAg gene; P is for polymerase gene X transactivator, involved in virus carcinogenesis [24] . Hepatitis C virus is a wrapped flavivirus with a 30 to 60-nm icosahedral capsid diameter. The genome is a positive single-stranded RNA of 9600 base pairs coding for ten proteins from a single reading frame [24] . Both viruses are involved in the onset of liver cancer, which represents the fifth most diagnosed cancer in men in the world, but the second global cause of death from cancer. In women, it occupies the 7th place and 6th leading cause of death. In 2008, about 748,300 cases were recorded for 695,900 deaths worldwide, half being registered in China. [25] The highest rates are recorded in the less developed countries especially in Western Africa, while the lowest rates are found in Europe.
Of all cancers of the liver, hepatocellular carcinoma (HCC) is the most common histological type covering 70% -85% of the total liver cancer. Cholangiocarcinoma, although rare, is frequently observed in Thailand and East Asia [26] . The HCC is the third leading cause of death by cancer in the world with 77% of cases in developing countries (23% in developed countries). In Africa, it is the second leading cause of cancer in men and the third in women. The high incidence in sub-Saharan Africa is related to chronic infection with HBV and HCV [26] . Around 5% -8% of immunocompetent adults and 30% to 40% of im- 
Epstein-Barr Virus (EBV) and Burkitt's Lymphoma
EBV or human herpes virus type 4 is a ubiquitous enveloped lymphotropic virus of the Gammaherpesvirinae subfamily. The genome is a linear double-stranded DNA from 175 Kb to icosahedral capsid coding for proteins 100 -150 divided into several unique domains separated by internal repeats 1 to 4 (IR Internal Repeats). In the world more than 95% of individuals are infected mainly through saliva before adulthood, although a small proportion develops mononucleosis.
In sub-Saharan Africa, almost all children are infected from mother to child with EBV before the age of 5 years [29] . EBV is implicated in Burkitt's lymphoma (BL) that is endemic in Africa, in nasopharyngeal cancers, in Hodgkin's disease and non-Hodgkin lymphoma (NHL) in immunosuppressed patients (transplant, AIDS).
Burkitt's lymphoma is a NHL of the lymphatic system that targets on Blymphocytes within the germinal center of lymph nodes. It was described in 1957 by
Denis Burkitt in Kampala (Uganda). It is characterized by the proliferation and deregulation of the c-myc gene [30] . It represents 35% to 50% of NHL in children and 2% of NHL in adults. Three main types are described: endemic BL, sporadic BL and BL associated with HIV infection [31] . In all three forms, the lymphoma that has become the leading cause of death in men and the fourth among women in Africa [36] .
African KS is endemic in areas with high incidence of malaria and BL. After a chronic course, death occurs 10 -15 years after onset (15) . Prevalence in Africa is very high, especially in Uganda and 57% of children are infected before the first sexual intercourse compared to 2% -5% in developed countries [37] .
HTLV-1 and Adult T Leukemia/Lymphoma (ATL)
HTLV-1 is an exogenous oncogenic retrovirus 80 -110 nm in diameter belonging to the Delta-retrovirus subfamily, identified in 1980 by Gallo (USA) [38] . The viral genome is a positive single-stranded RNA of 9000 bp present in two copies, flanked by two Long Terminal Repeats (LTR) between which lie the usual three genes of the family, Gag, Pol and Env, and pX gene that encodes for two regulatory proteins (Tax and Rex) involved in the oncogenic process [39] . Contrary to the mechanism of oncogenic retroviruses involving cis-activators or transducers, HTLV-1 has no viral oncogene similar to cellular proto-oncogene (v-onc) and is therefore not responsible for the malignant process. However, the Tax gene plays an important role in replication and cell transformation and is able to immortalize human T lymphocytes in cooperation with the ras oncogene.
The inhibition of the promoter of β-cell polymerase (role in DNA repair) by the Tax protein promotes the early occurrence of cytogenetic abnormalities. The complexity of the transformation mechanism of HTLV-1 involves altering of either the expression (repression or activation of the promoter) or function (inactivation or modification by direct binding of the cellular protein) of several proteins that are involved in the control of cell cycle (p53, p21, cyclin D2, p16, cyclin D3), in the survival of the cell (Bax, Bcl-2, NF-kB, c-fos) or in the proliferation or activation of the cell (IL-2, IL-15, GM-CSF). The Rex protein on the other hand increases the expression of certain cellular messenger RNAs encoding such as the alpha chain of the receptor for IL-2 [40] . Recently, has been shown the important role of the HBZ protein in cell proliferation whose expression is maintained in the adult T leukemia/lymphoma (ATL). In the end, epigenetic dysregulation, such as methylation of promoters and miRNA deregulation has also been demonstrated in ATL [41] .
Epidemiologically, the virus possesses a high genetic stability despite the existence of four major molecular variants according to the geographic area of occurrence: cosmopolitan subtype (A); subtype in Central Africa (B); Melanesian subtype (C); and pygmies of Central Africa subtype (D) [42] . Tropical Africa and Central Africa (Gabon, RDC) represent areas with high endemicity [38] . Clinically HTLV-1 causes two severe diseases: adult T leukemia/lymphoma and chronic myelopathy. The former ATL, an adult lymphoid malignancy, has been divided in three clinical forms: acute rapidly fatal forms, chronic form, and slowly progressive indolent "smoldering" form (5%), which may progress to either acute or chronic form. Chronic myelopathy is characterized by spastic paraparesis (Tropical Spastic Paraparesis or Human Associated Myelopathy HTLV-1; TSP/HAM) which begins around 40 -50 years. In the world, 15 to 25 million people are infected by HTLV-1, but only 3% -6% develop ATL or TSP/ HAM [38] .
Human Immunodeficiency Virus (HIV1 and HIV2) and Associated Cancers
HIV is a retrovirus belonging to the Lentivirinae subfamily. It is in the form of a spherical particle of from 90 to 120 nm in diameter bristling spicules. The genetic similarity is used to classify strains into types, groups and subtypes. There are two major types: HIV1 and HIV2 that have 42% genomic homology. The viral genome consists of two identical single-stranded RNA molecules of 9181 bp and has nine open reading frames. Three of these frames encode polyproteins Gag, Gag-Pol and Env, which are subsequently cleaved into individual proteins. The other six reading frames are: tat and rev genes that encode regulatory viral proteins essential for viral replication; genes nef, vif, vpr and vpu that encode proteins but remain accessories required for viral replication and pathogenesis in vivo. HIV2 has the vpu gene in place of the vpx gene [37] .
The great variability of HIV is linked to nucleotide incorporation errors provoked by reverse transcriptase during reverse transcription of viral RNA into viral DNA. The error rate is associated with a dynamic high viral replication resulting in the accumulation of many viral variants. This variability provides the virus with a great adaptability and allows it to escape the immune system of the host. The HIV1 are classified into three groups, M, N and O. Group M viruses represent the vast majority of characterized isolates. Phylogenetic analysis distinguish currently ten subtypes, A to J, with a 20% to 30% difference in homology of the env gene [38] .
In Africa, all subtypes of group M HIV-1 are present, with a very heterogeneous distribution and variability within subtypes. In the Great Lakes region, subtypes A and D are the most common. Subtype C prevails in Ethiopia and Southern Africa (together with subtype B). In West and Central Africa, while subtype A predominates, all other subtypes have been reported. In Cameroon, we found the highest prevalence of group O HIV-1 and early identification of group N HIV-1 isolate [38] .
HIV is a global public health problem with more than 25 million deaths worldwide and at least 33 [40] .
Infection with HIV belongs to the pathology group of acquired immunodeficiency syndrome (AIDS) that allows for opportunistic infections. Among such infections, the so-called cancer "ranking" AIDS are responsible for cancers observed in HIV seropositive patients. Kaposi's sarcoma (the most common tumors in patients infected in Africa), the primary central nervous system lymphoma (PCNSL), Burkitt's lymphoma and cervical cancer are all associated with oncogenic viruses [41] [42] . However, despite the decrease in the incidence of non-Hodgkin lymphoma and Kaposi's sarcoma due to highly active antiretroviral therapy (HAART), the incidence of viral infections on virus-induced cancers remains largely increased (by at least a factor 20) compared to the general population [42] . In addition, an increased risk of developing other "non-AIDS-defining" cancers is not negligible in the lung, liver, and Hodgkin's disease [42] .
Conclusion
Virus-induced cancers should be regarded as a public health problem in sub-Saharan Africa. The epidemic situation relative to these diseases reflects the magnitude of The framework of cooperation and transfer of knowledge between countries of the South should be amplified in order to launch a dynamic over the continent.
This constitutes another major capital lever to specifically control virus-induced cancers in Africa.
